Genetic mimicry of target gene effect weighted on Apo-B or Apo-A1 also retrieved similar results (Fig. 5, Table S13), although genetic mimicry of LDLR inhibition equivalent to 1 SD Apo-B decrease was suggestively associated with higher migraine risk (Finngen dataset: OR = 1.13, [95% CI, 0.93–1.39], p = 0.22; Choquet dataset: OR = 1.13, [95% CI, 1.01–1.27], p = 0.03; pooled estimates: OR = 1.13, [95% CI, 1.03–1.25], p = 0.01). This evidence concerns the gene APOA1 and migraine disorder.